Avidity-optimized TCR-T cells target KRAS neoantigens for potent cancer clearance and tumor microenvironment remodeling
TCR3 may be useful for KRAS neoantigen-targeted clinical immunotherapy, help resolve cancer immune escape, and enhance clinical effectiveness and safety.
Authors
- W Chen
- Bingling Wu
- Zhaoduan Liang
- Yi Li
- Wenxuan Cai
- Ye Tian
- Fengqiong Guan
Institutions
- Chinese Academy of Sciences (CN)
- Guangzhou Institutes of Biomedicine and Health (CN)
- Guangzhou Regenerative Medicine and Health Guangdong Laboratory (CN)
- Cellular Therapeutics (United Kingdom) (GB)
- State Key Laboratory of Respiratory Disease (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.3389/fimmu.2026.1736294
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China